vs
Beam Therapeutics Inc.（BEAM）与牛津地产（IIPR）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是牛津地产的1.7倍（$114.1M vs $66.7M），Beam Therapeutics Inc.净利率更高（214.1% vs 47.8%，领先166.3%），Beam Therapeutics Inc.同比增速更快（279.5% vs -13.1%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
BEAM vs IIPR — 直观对比
营收规模更大
BEAM
是对方的1.7倍
$66.7M
营收增速更快
BEAM
高出292.7%
-13.1%
净利率更高
BEAM
高出166.3%
47.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $66.7M |
| 净利润 | $244.3M | $31.8M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 47.8% |
| 净利率 | 214.1% | 47.8% |
| 营收同比 | 279.5% | -13.1% |
| 净利润同比 | 370.4% | -20.4% |
| 每股收益（稀释后） | $2.53 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMIIPR
| Q4 25 | $114.1M | $66.7M | ||
| Q3 25 | — | $64.7M | ||
| Q2 25 | — | $62.9M | ||
| Q1 25 | — | $71.7M | ||
| Q4 24 | — | $76.7M | ||
| Q3 24 | — | $76.5M | ||
| Q2 24 | — | $79.8M | ||
| Q1 24 | — | $75.5M |
净利润BEAMIIPR
| Q4 25 | $244.3M | $31.8M | ||
| Q3 25 | — | $29.3M | ||
| Q2 25 | — | $26.0M | ||
| Q1 25 | — | $31.1M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $40.2M | ||
| Q2 24 | — | $42.0M | ||
| Q1 24 | — | $39.4M |
营业利润率BEAMIIPR
| Q4 25 | -15.3% | 47.8% | ||
| Q3 25 | — | 45.5% | ||
| Q2 25 | — | 45.9% | ||
| Q1 25 | — | 47.4% | ||
| Q4 24 | — | 54.7% | ||
| Q3 24 | — | 54.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | — | 55.7% |
净利率BEAMIIPR
| Q4 25 | 214.1% | 47.8% | ||
| Q3 25 | — | 45.3% | ||
| Q2 25 | — | 41.4% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | 52.6% | ||
| Q1 24 | — | 52.3% |
每股收益（稀释后）BEAMIIPR
| Q4 25 | $2.53 | $1.07 | ||
| Q3 25 | — | $0.97 | ||
| Q2 25 | — | $0.86 | ||
| Q1 25 | — | $1.03 | ||
| Q4 24 | — | $1.35 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.44 | ||
| Q1 24 | — | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $47.6M |
| 总债务越低越好 | — | $393.7M |
| 股东权益账面价值 | $1.2B | $1.8B |
| 总资产 | $1.5B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资BEAMIIPR
| Q4 25 | $1.2B | $47.6M | ||
| Q3 25 | — | $41.9M | ||
| Q2 25 | — | $104.9M | ||
| Q1 25 | — | $133.3M | ||
| Q4 24 | — | $151.2M | ||
| Q3 24 | — | $172.4M | ||
| Q2 24 | — | $160.9M | ||
| Q1 24 | — | $173.5M |
总债务BEAMIIPR
| Q4 25 | — | $393.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BEAMIIPR
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.0B |
总资产BEAMIIPR
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.4B |
负债/权益比BEAMIIPR
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $198.2M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | 6.22× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMIIPR
| Q4 25 | $-83.3M | $198.2M | ||
| Q3 25 | — | $45.6M | ||
| Q2 25 | — | $48.4M | ||
| Q1 25 | — | $54.2M | ||
| Q4 24 | — | $258.4M | ||
| Q3 24 | — | $64.9M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $71.6M |
自由现金流BEAMIIPR
| Q4 25 | $-87.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BEAMIIPR
| Q4 25 | -76.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BEAMIIPR
| Q4 25 | 3.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率BEAMIIPR
| Q4 25 | -0.34× | 6.22× | ||
| Q3 25 | — | 1.56× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.75× | ||
| Q4 24 | — | 6.46× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
IIPR
暂无分部数据
